New Products & Services
Newark, CA--The FDA has approved for marketing Novasys Medical's Renessa System, a treatment for stress urinary incontinence due to hypermobility in women unresponsive to conservative care who are not candidates for surgical therapy. The 20-minute outpatient treatment involves applying controlled heat to tissue in the lower urinary tract, denaturing collagen at multiple small sites to increase tissue resistance to involuntary leakage during increased intra-abdominal pressure.
Outpatient SUI treatment approved for marketing
Newark, CA-The FDA has approved for marketing Novasys Medical's Renessa System, a treatment for stress urinary incontinence due to hypermobility in women unresponsive to conservative care who are not candidates for surgical therapy. The 20-minute outpatient treatment involves applying controlled heat to tissue in the lower urinary tract, denaturing collagen at multiple small sites to increase tissue resistance to involuntary leakage during increased intra-abdominal pressure.
A multicenter clinical trial in 170 women who underwent the Renessa treatment resulted in reduced incontinence episodes, pad use, and leak severity for the majority of study participants, Novasys said.
Software checks medical, pharmaceutical spelling
For more information, visit
Planning tool expedites brachytherapy treatment
Palo Alto, CA-The Vitesse system from Varian Medical Systems, Inc., combines the company's VariSeed planning system and its BrachyVision 3-D planning software in an optional workflow module that allows physicians to obtain prostate images with high-dose-rate catheters in place and export the data digitally to the 3-D planning software for treatment planning. This system can reduce the time required for brachytherapy treatment planning by two-thirds and can reduce the need for overnight hospitalization, according to the manufacturer.
For more information, visit
Brochure helps patients understand clinical trials
Internal server error